Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYLVI: Synthetic vs Natural Estrogen in Combined Oral Contraception
NCT02352090Phase 4Completed
- Sponsor
- Helsinki University Hospital
- Start
- Apr 2015
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of estradiol valerate in contraception, sponsored by Helsinki University Hospital. Primary endpoint: Matsuda Index - Whole Body Insulin Sensitivity Index at 9 weeks. Started Apr 2015; status: completed.
02
Drugs
estradiol valerate
03
Conditions
contraception
Beyond the preview
Go deeper on NCT02352090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02352090.